Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) said Steve Lisi, Chairman & CEO, will participate in two investor conferences in early February 2026: the Noble Capital Markets Emerging Growth Virtual Equity Conference (Feb 4–5) and the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Feb 9–11) in Snowbird, UT.
The Noble event includes a corporate presentation on Feb 5 at 2:00 PM ET plus one-on-one meetings; the presentation will be webcast live and archived on the company website for 90 days following the event. BTIG participation is scheduled as one-on-one meetings.
Positive
- None.
Negative
- None.
News Market Reaction – XAIR
On the day this news was published, XAIR declined 5.93%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -14.4% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $737K from the company's valuation, bringing the market cap to $12M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
XAIR fell 9.88% while several medical device peers also traded lower (e.g., AIMD -5.13%, INBS -2.57%, NVNO -10.48%), indicating pressure across related names rather than a company-specific move from this conference notice.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Earnings call scheduled | Neutral | -9.9% | Set date for Q3 FY2026 results call and webcast in mid-February. |
| Jan 14 | Private placement | Negative | -14.2% | Announced $5.0M at-the-market private placement with new warrants issued. |
| Jan 13 | Subsidiary transaction | Positive | +150.0% | Agreed to sell 85% of NeuroNOS for equity, cash, and milestones. |
| Dec 30 | Management change | Neutral | -0.8% | Appointed new CFO with option grant and prior controller resuming role. |
| Dec 17 | Commercial expansion | Positive | +2.7% | Signed new LungFit PH distribution deals expanding to 39 countries. |
Recent stock moves often aligned with news tone: financing and dilution-related items saw declines, while strategic transactions and commercial updates saw gains.
Over the past few months, Beyond Air issued a mix of strategic, financing, and corporate updates. An autism‑focused NeuroNOS transaction on Jan 13, 2026 coincided with a 150% move, while a $5.0M private placement on Jan 14, 2026 saw shares fall. Operationally, new LungFit PH distribution agreements on Dec 17, 2025 modestly lifted the stock. Leadership changes, including a new CFO effective Jan 5, 2026, had limited impact. Today’s conference participation fits within this pattern of frequent communications.
Regulatory & Risk Context
Beyond Air has an active Form S-3/A shelf amendment dated Sep 30, 2025, described as a technical update to add a legal opinion and related consent, with prior offering mechanics detailed in associated prospectus filings. The registration remains in place through Sep 30, 2028 and has been used at least once, as indicated by a 424B3 filing on Dec 16, 2025.
Market Pulse Summary
The stock moved -5.9% in the session following this news. A negative reaction despite this routine conference notice would fit a pattern where financing and capital-structure concerns weigh on sentiment. The stock recently closed at $1.46, far under its $10.40 52‑week high, and below the $2.64 200‑day MA. Recent private placement activity, an effective equity line, and ongoing losses disclosed in filings provide context for why downside moves have appeared after otherwise benign updates.
AI-generated analysis. Not financial advice.
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Capital Markets Emerging Growth Virtual Equity Conference being held February 4th to 5th.
| BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | ||
| Format: | One-on-one meetings | |
| Conference Dates: | February 9thto 11th | |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air | |
| Noble Capital Markets Emerging Growth Virtual Equity Conference | ||
| Format: | Corporate presentation and one-on-one meetings | |
| Presentation Date: | Thursday, February 5that 2:00pm ET | |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air | |
| Live Webcast link: | Attendees interested in viewing the live presentation can register for this event at no cost, here: Virtual Equity Conference Registration. An archive of the webcast will be available at https://www.beyondair.net/news-events/eventsfor 90 days following the event | |
If you are interested in requesting a one-on-one meeting at either of the conferences, please contact your respective bank representative to schedule accordingly.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
CONTACTS:
Investor Relations
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will Beyond Air (XAIR) present at the Noble Capital Markets Virtual Equity Conference in 2026?
Which conferences will Beyond Air (XAIR) attend in February 2026?
Will Beyond Air's (XAIR) Noble Capital presentation be available via webcast?
Who is representing Beyond Air (XAIR) at the February 2026 investor conferences?
How can investors request a one-on-one meeting with Beyond Air (XAIR) at the conferences?
What format will Beyond Air (XAIR) use at the BTIG MedTech conference on Feb 9–11, 2026?
